KAKAO VE TEOBROMİNİN NÖRODEJENERASYONDAKİ ETKİSİ: NÖROPROTEKTİF VE KANNABİNOİDERJİK MEKANİZMALAR

Abstract

Bu derleme, kakao ve çikolatada bulunan teobromin ve anandamit ile N-açiletanolaminler (NAE'ler) dahil olmak üzere endokannabinoit ile ilgili bileşiklerin nöropsikofarmakolojik etkileri ve nörodejeneratif hastalıklarla ilişkileri hakkındaki mevcut deneysel ve klinik kanıtları eleştirel bir şekilde değerlendirmeyi amaçlamaktadır. Endokannabinoit sistemle ilgili bileşikler kakao ve çikolatada mevcuttur; ancak, doğrudan psikoaktif etkilere neden olmak için gereken miktarlar diyet yoluyla tüketimle elde edilemez. NAE'ler, yağ asidi amid hidrolazın (FAAH) inhibisyonu yoluyla endokannabinoit sinyallemesini dolaylı olarak modüle edebilir, bu da endojen anandamit seviyelerinin artmasına ve potansiyel olarak çikolatanın hedonik ve nöropsikofarmakolojik etkilerine katkıda bulunabilir. Buna paralel olarak, teobromin, Alzheimer ve Parkinson hastalıklarının preklinik modellerinde olumlu farmakokinetik özellikler ve antioksidan, antienflamatuvar ve nöroprotektif etkiler göstermektedir. Deneysel bulgular oksidatif stres, nöroenflamasyon ve sinaptik disfonksiyonun modülasyonunu desteklese de, klinik kanıtlar sınırlı ve heterojendir. Ek olarak, kakao işleme süreçleri polifenol içeriğini ve biyoaktivitesini etkiler ve diğer nöroprotektif besin takviyeleriyle kombinasyonları sinerjik faydalar sağlayabilir. Genel olarak, kakao kaynaklı bileşikler, özellikle teobromin, nörodejenerasyonla ilgili yolların umut vadeden modülatörlerini temsil etmektedir; ancak, terapötik önemlerini, optimal dozlarını ve güvenliklerini tanımlamak için standartlaştırılmış, iyi tasarlanmış ve uzun vadeli klinik çalışmalara ihtiyaç duyulmaktadır.

Keywords

• Anandamit
• çikolata
• nöroprotektif
• Theobroma cacao
• teobromin

Ethical Statement

Bu çalışma için etik kurul onayı gerekmemektedir.

Cocoa and theobromine in neurodegeneration: Neuroprotective and cannabinoidergic mechanisms

Abstract

This review aims to critically evaluate current experimental and clinical evidence on the neuropsychopharmacological effects of theobromine and endocannabinoid-related compounds, including anandamide and N-acylethanolamines (NAEs), in cocoa and chocolate, and their relevance to neurodegenerative diseases. Endocannabinoid system–related compounds are present in cocoa and chocolate; however, the amounts required to induce direct psychoactive effects cannot be achieved through dietary consumption. NAEs may indirectly modulate endocannabinoid signaling via inhibition of fatty acid amide hydrolase (FAAH), leading to increased endogenous anandamide levels and potentially contributing to the hedonic and neuropsychopharmacological effects of chocolate. In parallel, theobromine shows favorable pharmacokinetic properties, while preclinical studies suggest potential antioxidant, anti-inflammatory, and neuroprotective effects of theobromine and other cocoa-derived compounds in models relevant to Alzheimer’s and Parkinson’s diseases. Although experimental findings support modulation of oxidative stress, neuroinflammation, and synaptic dysfunction, clinical evidence remains limited and heterogeneous. Additionally, cocoa processing affects polyphenol content and bioactivity, and combinations with other neuroprotective nutraceuticals may provide synergistic benefits. Overall, cocoa-derived compounds particularly theobromine represent promising modulators of neurodegeneration-related pathways; however, standardized, well-designed, and long-term clinical studies are needed to define their therapeutic relevance, optimal dosing, and safety.

Keywords

• Anandamide
• chocolate
• neuroprotective
• Theobroma cacao
• theobromine

Ethical Statement

This study does not require ethics approval.

References

1. Przedborski S, Vila M, Jackson-Lewis V. Series introduction: Neurodegeneration: What is it and where are we? J Clin Invest. 2003;111(1):3–10.
2. Gitler AD, Dhillon P, Shorter J. Neurodegenerative disease: models, mechanisms, and a new hope. Dis Model Mech. 2017;10(5):499–502.
3. Hou Y, Dan X, Babbar M, Wei Y, Hasselbalch SG, Croteau DL, et al. Ageing as a risk factor for neurodegenerative disease. Nat Rev Neurol. 2019;15(10):565–581.
4. Mey GM, Mahajan KR, DeSilva TM. Neurodegeneration in multiple sclerosis. WIREs Mech Dis. 2023;15(1):e1583.
5. World Alzheimer Day, September 21, 2024 [Internet]. Ankara: Republic of Türkiye Ministry of Health; 2024 [cited 2025 Apr 19]. Available from: https://hsgm.saglik.gov.tr/tr/haberler-16/21-eylul-2024-dunya-alzheimer-gunu.html
6. World Health Organization. Parkinson disease fact sheet [Internet]. Geneva: WHO; 2023 [cited 2025 Apr 19]. Available from: https://www.who.int/news-room/fact-sheets/detail/parkinson-disease
7. Luo Y, Qiao L, Li M, Wen X, Zhang W, Li X. Global, regional, national epidemiology and trends of Parkinson’s disease from 1990 to 2021: findings from the Global Burden of Disease Study 2021. Front Aging Neurosci. 2025;16:1498756.
8. Atlas of MS. Number of people with MS worldwide [Internet]. 2023 [cited 2025 Apr 19]. Available from: https://www.atlasofms.org/map/global/epidemiology/number-of-people-with-ms

9. Oñatibia-Astibia A, Franco R, Martínez-Pinilla E. Health benefits of methylxanthines in neurodegenerative diseases. Mol Nutr Food Res. 2017;61(6):1600670.
10. Lee JJ. Pharmacological treatment in Parkinson’s disease. J Korean Neurol Assoc. 2019;37(4):335–344.
11. Barnes PJ. Theophylline. Pharmaceuticals. 2010;3(3):725–747.
12. Arendash GW, Cao C. Caffeine and coffee as therapeutics against Alzheimer’s disease. J Alzheimers Dis. 2010;20(1):117–126.
13. Eskelinen MH, Kivipelto M. Caffeine as a protective factor in dementia and Alzheimer’s disease. J Alzheimers Dis. 2010;20(1):167–174.
14. Postuma RB, Lang AE, Munhoz RP, Charland K, Pelletier A, Moscovich M, et al. Caffeine for treatment of Parkinson disease: a randomized controlled trial. Neurology. 2012;79(7):651–658.
15. Gates S, Miners JO. Cytochrome P450 isoform selectivity in human hepatic theobromine metabolism. Br J Clin Pharmacol. 1999;47(3):299–305.
16. Snyder SH, Katims JJ, Annau Z, Bruns RF, Daly JW. Adenosine receptors and behavioral actions of methylxanthines. Proc Natl Acad Sci U S A. 1981;78(5):3260–3264.
17. Bhat JA, Gupta S, Kumar M. Neuroprotective effects of theobromine in transient global cerebral ischemia–reperfusion rat model. Biochem Biophys Res Commun. 2021;571:74–80.
18. Basir HS, Mirazi N, Komaki A, Ramezani M, Hosseini A. Cacao ameliorates amyloid beta-induced cognitive and non-cognitive disturbances. Neurosci Insights. 2024;19:26331055241280638.
19. Travassos M, Santana I, Baldeiras I, Tsolaki M, Gkatzima O, Sermin G, et al. Does caffeine consumption modify cerebrospinal fluid amyloid-β levels in patients with Alzheimer’s disease? J Alzheimers Dis. 2015;47(4):1069–1078.
20. Xu K, Xu YH, Chen JF, Schwarzschild MA. Neuroprotection by caffeine: time course and role of its metabolites in the MPTP model of Parkinson’s disease. Neuroscience. 2010;167(2):475–481.
21. Zeli C, Lombardo M, Storz MA, Ottaviani M, Rizzo G. Chocolate and cocoa-derived biomolecules for brain cognition during ageing. Antioxidants. 2022;11(7):1353.
22. Scholey A, Owen L. Effects of chocolate on cognitive function and mood: a systematic review. Nutr Rev. 2013;71(10):665–681.
23. Francis ST, Head K, Morris PG, Macdonald IA. The effect of flavanol-rich cocoa on the fMRI response to a cognitive task in healthy young people. J Cardiovasc Pharmacol. 2006;47(Suppl 2):S215–S220.
24. Field DT, Williams CM, Butler LT. Consumption of cocoa flavanols results in an acute improvement in visual and cognitive functions. Physiol Behav. 2011;103(3–4):255–260.
25. Okhah AA, Enogieru AB. Antioxidant and protective activities of aqueous Theobroma cacao seed extract against aluminium-induced hippocampal toxicity in Wistar rats. Niger J Biochem Mol Biol. 2023;38(4):197–205.
26. Ried K, Sullivan TR, Fakler P, Frank OR, Stocks NP. Effect of cocoa on blood pressure. Cochrane Database Syst Rev. 2012;(8):CD008893.
27. Ramiro-Puig E, Casadesús G, Lee HG, Zhu X, McShea A, Perry G, et al. Neuroprotective effect of cocoa flavonoids on in vitro oxidative stress. Eur J Nutr. 2009;48:54–61.
28. Mendiola-Precoma J, Padilla K, Rodríguez-Cruz A, Berumen LC, Miledi R, García-Alcocer G. Theobromine-induced changes in A1 purinergic receptor gene expression and distribution in a rat brain Alzheimer’s disease model. J Alzheimers Dis. 2016;55(3):1273–1283.
29. Cova I, Leta V, Mariani C, Pantoni L, Pomati S. Exploring cocoa properties: is theobromine a cognitive modulator? Psychopharmacology. 2019;236:561–572.
30. Shultz S. Cocoa. J Agric Food Inf. 2006;7(2-3):17–31.
31. Tınmaz O, Altunbağ E, Yıldırım Ö. The use of chocolate and cocoa in recipe books published in the Ottoman and Turkey between 1880–1980. J Gastronomy Hosp Travel. 2022;5(1):288–299.
32. Özkaya FD, Özkaptan T. Latin Amerika uygarlıklarının mirası kakaonun tarihçesi ve çikolataya dönüşümü. J Tourism Gastronomy Stud. 2016;31:41.
33. Verna R. The history and science of chocolate. Malays J Pathol. 2013;35(2):111.
34. Dillinger TL, Barriga P, Escárcega S, Jimenez M, Lowe DS, Grivetti LE. Food of the gods: cure for humanity? A cultural history of the medicinal and ritual use of chocolate. J Nutr. 2000;130(8):2057S–2072S.
35. Ozturk G, Young GM. Food evolution: the impact of society and science on the fermentation of cocoa beans. Compr Rev Food Sci Food Saf. 2017;16(3):431–455.
36. Bhattacharjee R, Lava Kumar P. Cacao. In: Kole C, editor. Technical Crops. Vol 6. Berlin: Springer; 2007. p. 127–142.
37. Wollgast J, Anklam E. Review on polyphenols in Theobroma cacao: changes in composition during the manufacture of chocolate and methodology for identification and quantification. Food Res Int. 2000;33(6):423–447.
38. Shahidi F, Ambigaipalan P. Phenolics and polyphenolics in foods, beverages and spices: antioxidant activity and health effects–a review. J Funct Foods. 2015;18:820–897.
39. Martin MÁ, Goya L, Ramos S. Antidiabetic actions of cocoa flavanols. Mol Nutr Food Res. 2016;60(8):1756–1769.
40. Strat KM, Rowley TJ IV, Smithson AT, Tessem JS, Hulver MW, Liu D, et al. Mechanisms by which cocoa flavanols improve metabolic syndrome and related disorders. J Nutr Biochem. 2016;35:1–21.
41. Karatas O, Karabay A, Alici T. The effects of long-term cocoa flavanols intake on cognitive functions and mood, and the physiological mechanisms underlying these effects: a literature review. Turk Psikoloji Yazilari. 2022;25(49):21–26.
42. Andújar I, Recio MC, Giner RM, Ríos J. Cocoa polyphenols and their potential benefits for human health. Oxid Med Cell Longev. 2012;2012:906252.
43. Nehlig A. The neuroprotective effects of cocoa flavanol and its influence on cognitive performance. Br J Clin Pharmacol. 2013;75(3):716–727.
44. Magrone T, Russo MA, Jirillo E. Cocoa and dark chocolate polyphenols: from biology to clinical applications. Front Immunol. 2017;8:271757.
45. Matsuzaki K, Sugimoto N, Hossain S, Islam R, Sumiyoshi E, Hashimoto M, et al. Theobromine improves hyperactivity, inattention, and working memory via modulation of dopaminergic neural function in the frontal cortex of spontaneously hypertensive rats. Food Funct. 2024;15(10):5579–5595.
46. Valada P, Alçada-Morais S, Cunha RA, Lopes JP. Theobromine targets adenosine receptors to control hippocampal neuronal function and damage. Int J Mol Sci. 2022;23(18):10510.
47. Smit HJ, Gaffan EA, Rogers PJ. Methylxanthines are the psycho-pharmacologically active constituents of chocolate. Psychopharmacology. 2004;176:412–419.
48. Rodrigues-Silva N. Chocolate: psychopharmacological aspects, mood, and addiction. In: Chocolate in Health and Nutrition. 2013. p. 421–435.
49. Herraiz T. Tetrahydro-β-carbolines, potential neuroactive alkaloids, in chocolate and cocoa. J Agric Food Chem. 2000;48(10):4900–4904.
50. Xie Z, Cao N, Wang C. A review on β-carboline alkaloids and their distribution in foodstuffs. Food Chem. 2021;348:129067.
51. McIsaac WM, Taylor D, Walker KE, Ho BT. 6-Methoxy-1,2,3,4-tetrahydro-β-carboline–α serotonin elevator 1. J Neurochem. 1972;19(4):1203–1206.
52. Bertazzo A, Comai S, Mangiarini F, Chen S. Composition of cacao beans. In: Chocolate in Health and Nutrition. 2013. p. 105–117.
53. Gao L, Ge W, Peng C, Guo J, Chen N, He L. Association between dietary theobromine and cognitive function in a representative American population. J Prev Alzheimers Dis. 2022;9(3):449–457.
54. Tunick MH, Nasser JA. The chemistry of chocolate and pleasure. In: Sex, Smoke, and Spirits: The Role of Chemistry. Washington, DC: ACS; 2019. p. 33–41.
55. Bruinsma K, Taren DL. Chocolate: food or drug? J Am Diet Assoc. 1999;99(10):1249–1256.
56. Schifano F, Magni G. MDMA abuse: psychopathological features and craving for chocolate: a case series. Biol Psychiatry. 1994.
57. Di Tomaso E, Beltramo M, Piomelli D. Brain cannabinoids in chocolate. Nature. 1996;382(6593):677–678.
58. Sengupta T, Mohanakumar KP. 2-Phenylethylamine causes mitochondrial complex-I inhibition and psychomotor dysfunctions in mice. Neurochem Int. 2010;57(6):637–646.
59. Sałaga M, Sobczak M, Fichna J. Inhibition of FAAH as a novel therapeutic strategy. Eur J Pharm Sci. 2014;52:173–179.
60. Eggleston KM, White T. Chocolate and pain tolerance. In: Chocolate in Health and Nutrition. 2013. p. 437–447.
61. Smalheiser NR. A neglected link between dietary psychoactive ingredients and consciousness-altering drugs. Front Psychiatry. 2019;10:591.
62. Fredholm BB, Smit HJ. Theobromine and the pharmacology of cocoa. In: Methylxanthines. 2011. p. 201–234.
63. Smit HJ, Rogers PJ. Potentially psychoactive constituents of cocoa-containing products. Leatherhead Food RA Publishing; 2001. p. 325–349.
64. Svíženská I, Dubový P, Šulcová A. Cannabinoid receptors CB1 and CB2. Pharmacol Biochem Behav. 2008;90(4):501–511.
65. Mukherjee PK. Bioactive phytocomponents and their analysis. In: Quality Control and Evaluation of Herbal Drugs. Elsevier; 2019. p. 237–328.
66. PubChem. Theobromine. 2025. Available from: https://pubchem.ncbi.nlm.nih.gov/compound/5429
67. Eteng MU, Eyong EU, Akpanyung EO, Agiang MA, Aremu CY. Recent advances in caffeine and theobromine toxicities: a review. Plant Foods Hum Nutr. 1997;51:231–243.
68. Zhang M, Zhang H, Jia L, Zhang Y, Qin R, Xu S, et al. Health benefits and mechanisms of theobromine. J Funct Foods. 2024;115:106126.
69. Cardinali DP. Methylxanthines: possible mechanisms of action in brain. Trends Pharmacol Sci. 1980;1(2):405–407.
70. Martínez-Pinilla E, Oñatibia-Astibia A, Franco R. The relevance of theobromine for the beneficial effects of cocoa consumption. Front Pharmacol. 2015;6:126866.
71. Bonati M, Latini R, Sadurska B, Riva E, Galletti F, Borzelleca JF, et al. Kinetics and metabolism of theobromine in male rats. Toxicology. 1984;30(4):327–341.
72. Tarka SM, Arnaud MJ, Dvorchik BH, Vesell ES. Theobromine kinetics and metabolic disposition. Clin Pharmacol Ther. 1983;34(4):546–555.
73. Gwaltney-Brant S. Chocolate intoxication. Vet Med. 2001;96(2):108–111.
74. Dolder LK. Methylxanthines: caffeine, theobromine, theophylline. In: Peterson ME, Talcott PA, editors. Small Animal Toxicology. Philadelphia: W.B. Saunders; 2013. p. 647–652.
75. Yanuartono Y. Chocolate poisoning in dogs: therapeutic management and prevention. J Vet Sci. 2020;38(2):175–187.
76. Soffietti MG, Nebbia C, Valenza F, Amedeo S, Re G. Toxic effects of theobromine on mature and immature male rabbits. J Comp Pathol. 1989;100(1):47–58.
77. Gans JH, Korson R, Cater MR, Ackerly CC. Effects of short-term and long-term theobromine administration to male dogs. Toxicol Appl Pharmacol. 1980;53(3):481–496.
78. Lee HW, Choi IW, Ha SK. Immunostimulatory activities of theobromine on macrophages via activation of MAPK and NF-κB signaling pathways. Curr Issues Mol Biol. 2022;44(9):4216–4228.
79. Kargul B, Özcan M, Peker S, Nakamoto T, Simmons WB, Falster AU. Evaluation of human enamel surfaces treated with theobromine: a pilot study. Oral Health Prev Dent. 2012;10(3):275–280.
80. Nakamoto T, Falster AU, Simmons WB Jr. Theobromine: a safe and effective alternative for fluoride in dentifrices. J Caffeine Res. 2016;6(1):1–9.
81. Baba S, Osakabe N, Kato Y, Natsume M, Yasuda A, Kido T, et al. Continuous intake of polyphenolic compounds containing cocoa powder reduces LDL oxidative susceptibility and improves HDL-cholesterol. Am J Clin Nutr. 2007;85(3):709–717.
82. Neufingerl N, Zebregs YE, Schuring EA, Trautwein EA. Effect of cocoa and theobromine consumption on serum HDL-cholesterol: a randomized controlled trial. Am J Clin Nutr. 2013;97(6):1201–1209.
83. van den Bogaard B, Draijer R, Westerhof BE, van den Meiracker AH, van Montfrans GA, van den Born BJ. Effects of cocoa with natural or high-dose theobromine on blood pressure. Hypertension. 2010;56(5):839–846.
84. Khan SR, Pearle MS, Robertson WG, Gambaro G, Canales BK, Doizi S, et al. Kidney stones. Nat Rev Dis Primers. 2016;2:16008.
85. Grases F, Rodriguez A, Costa-Bauza A. Theobromine inhibits uric acid crystallization. PLoS One. 2014;9(10):e111184.
86. Morice AH, McGarvey L, Pavord ID, Higgins B, Chung KF, Birring SS. Theobromine for persistent cough: a randomized controlled trial. J Thorac Dis. 2017;9(7):1864–1872.
87. Sugimoto N, Miwa S, Hitomi Y, Nakamura H, Tsuchiya H, Yachie A. Theobromine inhibits glioblastoma proliferation via PDE4 and ERK/Akt/mTOR pathways. Nutr Cancer. 2014;66(3):419–423.
88. Judelson DA, Preston AG, Miller DL, Muñoz CX, Kellogg MD, Lieberman HR. Effects of theobromine and caffeine on mood and vigilance. J Clin Psychopharmacol. 2013;33(4):499–506.
89. Baggott MJ, Childs E, Hart AB, de Bruin E, Palmer AA, Wilkinson JE, et al. Psychopharmacology of theobromine in healthy volunteers. Psychopharmacology. 2013;228:109–118.
90. Mitchell ES, Slettenaar M, van der Meer N, Transler C, Jans L, Quadt F, et al. Differential contributions of theobromine and caffeine on mood and performance. Physiol Behav. 2011;104(5):816–822.
91. Li XY, Liu H, Zhang LY, Yang XT. Association between dietary theobromine and depression. BMC Psychiatry. 2022;22(1):769.
92. Fusar-Poli L, Gabbiadini A, Ciancio A, Vozza L, Signorelli MS, Aguglia E. Effects of cocoa-rich products on mood disorders: a systematic review and meta-analysis. Crit Rev Food Sci Nutr. 2022;62(28):7905–7916.
93. Yoneda M, Sugimoto N, Katakura M, Matsuzaki K, Tanigami H, Yachie A, et al. Theobromine upregulates BDNF and facilitates motor learning. J Nutr Biochem. 2017;39:110–116.
94. Tao X, Finkbeiner S, Arnold DB, Shaywitz AJ, Greenberg ME. Ca2+ influx regulates BDNF transcription via CREB. Neuron. 1998;20(4):709–726.
95. Heneka MT, van der Flier WM, Jessen F, Hoozemans JJM, Thal DR, Boche D, et al. Neuroinflammation in Alzheimer disease. Nat Rev Immunol. 2024;24:1–32.
96. Korczyn AD, Grinberg LT. Is Alzheimer disease a disease? Nat Rev Neurol. 2024;20(4):245–251.
97. Ademola IO, Oboh G, Ademosun AO. Comparative antioxidant and anticholinesterase properties of catechin, caffeine and theobromine. Niger J Biochem Mol Biol. 2024;39(2):91–98.
98. Abu-Elfotuh K, Tolba AM, Hussein FH, Hamdan AM, Rabeh MA, Alshahri SA, et al. Anti-Alzheimer activity of cocoa combinations in rat model. Pharmaceutics. 2023;15(8):2063.
99. Wang J, Varghese M, Ono K, Yamada M, Levine S, Tzavaras N, et al. Cocoa extracts reduce amyloid-β oligomerization. J Alzheimers Dis. 2014;41(2):643–650.
100. Valadez-Barba V, Juárez-Navarro K, Padilla-Camberos E, Díaz NF, Guerra-Mora JR, Díaz-Martínez NE. Parkinson’s disease: update on iPSC models. Neurologia (Engl Ed). 2023;38(9):681–694.
101. Fujimaki M, Saiki S, Li Y, Kaga N, Taka H, Hatano T, et al. Serum caffeine metabolites as biomarkers of early Parkinson disease. Neurology. 2018;90(5):e404–e411.
102. Wolz M, Schleiffer C, Klingelhöfer L, Schneider C, Proft F, Schwanebeck U, et al. Chocolate vs white chocolate in Parkinson’s disease. J Neurol. 2012;259:2447–2451.
103. Azzolin VF, Ribeiro EE, Sasso JS, Reis D, Bonotto NC, Turra BO, et al. Synergistic neuroprotective effects of cocoa seed husk and guarana. Nutr Neurosci. 2025;14(3):348.
104. Coe S, Andreoli D, George M, Collett J, Reed A, Cossington J, et al. Cocoa consumption and fatigue in Parkinson’s disease. Clin Nutr ESPEN. 2022;48:68–73.
105. Thompson AJ, Baranzini SE, Geurts J, Hemmer B, Ciccarelli O. Multiple sclerosis. Lancet. 2018;391(10130):1622–1636.
106. Tur C. Fatigue management in multiple sclerosis. Curr Treat Options Neurol. 2016;18:26.
107. Adibi A, Zandieh G, Zolfaghari B, Ashtari F, Shaygannejad V, Adibi I. Investigation of the effects of cocoa powder on fatigue severity in patients with relapsing-remitting multiple sclerosis: a randomized controlled trial. Clin Nutr Open Sci. 2024;55:136–148.
108. Pacher P, Bátkai S, Kunos G. The endocannabinoid system as an emerging target of pharmacotherapy. Pharmacol Rev. 2006;58(3):389–462.
109. Murillo-Rodríguez E, Poot-Ake A, Arias-Carrión O, Pacheco-Pantoja E, de la Fuente-Ortegón A, Arankowsky-Sandoval G. The emerging role of the endocannabinoid system in the sleep–wake cycle modulation. CNS Agents Med Chem. 2011;11(3):189–196.
110. Pertwee RG. Receptors and channels targeted by synthetic cannabinoid receptor agonists and antagonists. Curr Med Chem. 2010;17(14):1360–1381.